CommercialCoverageHigh impact
Extracorporeal Membrane Oxygenation (ECMO) (CPB 0546, reviewed 2025-08-21)
Aetna·Cardiothoracic Surgery, Critical Care, Pediatrics +3 more·Medical Policy
Effective date
Aug 21, 2025
We identified it
Aug 15, 2026
Summary
Aetna has updated its ECMO (Extracorporeal Membrane Oxygenation) medical policy (CPB 0546) effective 2025-08-21, establishing clear medical necessity criteria for neonates, children, and adults. The policy covers 26 specific CPT codes for ECMO initiation, daily management, cannula insertion/repositioning/removal, and related procedures when criteria are met, while designating numerous indications as experimental/investigational (including COVID-19, acute coronary syndromes, and pulmonary embolism without cardiac arrest). Billing teams must immediately verify patient eligibility against strict criteria and update claims submission workflows.
Action Required
Effective immediately (2025-08-21): Billing team must implement the following changes: (1) Update billing system to deny or route for manual review any ECMO claims (CPT 33946-33989, 33987-33989) that do not meet Aetna's specific medical necessity criteria for neonates (diagnosis list + gestational age ≥34 weeks + birth weight ≥2000g + age <10 days) or children/adults (high-risk reversible respiratory/cardiac failure unresponsive to conventional therapy or bridge-to-transplant/mechanical support scenarios); (2) Flag as experimental/investigational and deny claims for ECMO related to COVID-19, acute coronary syndromes, massive pulmonary embolism, type A aortic dissection, burns without ARDS/shock, drug overdose, sepsis (except refractory pediatric septic shock), status asthmaticus, and tuberculosis per policy; (3) Require providers to document all inclusion/exclusion criteria on operative reports and submit with claims; (4) Add prior authorization workflow requiring clinical documentation review before claim submission for all ECMO cases; (5) Train billing staff and providers on the distinction between covered and experimental indications to prevent claim rejections and appeals. Failure to implement these controls will result in high denial rates and payment delays for legitimate ECMO cases.